Published in Mol Ther on June 06, 2016
HIV-1 Tat and Viral Latency: What We Can Learn from Naturally Occurring Sequence Variations. Front Microbiol (2017) 0.75
MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res (2004) 168.89
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med (1996) 12.11
Cellular uptake of the tat protein from human immunodeficiency virus. Cell (1988) 10.19
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
The challenge of finding a cure for HIV infection. Science (2009) 8.41
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med (2007) 6.01
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell (2005) 5.71
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (1995) 4.95
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol (2000) 4.46
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol (2001) 3.86
Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity (2005) 3.70
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol (1993) 3.68
Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science (1995) 3.46
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Generation of HIV latency during thymopoiesis. Nat Med (2001) 2.91
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem (1999) 2.81
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med (2014) 2.76
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res (1989) 2.72
Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J (1988) 2.57
Site-directed, Ligase-Independent Mutagenesis (SLIM): a single-tube methodology approaching 100% efficiency in 4 h. Nucleic Acids Res (2004) 2.54
Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog (2009) 2.50
HIV: Shock and kill. Nature (2012) 2.45
Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J (2007) 2.37
Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell (1998) 2.23
Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol (1992) 1.97
Removal of endotoxin from recombinant protein preparations. Clin Biochem (1997) 1.95
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Immunologic strategies for HIV-1 remission and eradication. Science (2014) 1.70
Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein. J Virol (1990) 1.68
An integrated overview of HIV-1 latency. Cell (2013) 1.68
HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim. EMBO J (2002) 1.50
Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. Retrovirology (2016) 1.42
Apoptosis induced by HIV-1 infection of the central nervous system. J Clin Invest (1996) 1.40
Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations. J Virol Methods (2010) 1.38
Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J Virol (1999) 1.35
Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood (2013) 1.24
Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J Immunol (1993) 1.18
What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology (2009) 1.15
The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART. AIDS (2007) 1.12
Recombinant human immunodeficiency virus type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture. J Virol (1996) 1.04
HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood (2004) 0.99
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine (2009) 0.97
The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine (2009) 0.95
Full-length HIV-1 Tat protein necessary for a vaccine. Vaccine (2004) 0.87
HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int Rev Immunol (2009) 0.85
DDX5 facilitates HIV-1 replication as a cellular co-factor of Rev. PLoS One (2013) 0.84
A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies. Vaccine (2012) 0.80